An experimental siRNA treatment extended survival in SOD1 ALS mice
Original source
RNAi-mediated silencing of SOD1 profoundly extends survival and functional outcomes in ALS mice. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Studied in
- Human, Mouse
Related topics
Researchers developed a chemically stabilised small interfering RNA (siRNA) designed to reduce SOD1 production. When delivered into the brain ventricles, it extended survival, slowed disease progression and reduced signs of nerve damage in SOD1-G93A ALS mice.
Why this matters
The approach is aimed at SOD1-related ALS and may improve how strongly and widely SOD1 is suppressed in the central nervous system. These results come from mice, so they do not yet show that the treatment is safe or effective in people and do not change current treatment.
Limitations and context
This was preclinical research in a genetically engineered mouse model, not a human clinical trial. The treatment was administered intraventricularly, and the study does not establish its safety, effectiveness or appropriate delivery in people. Further research would be needed before its clinical value can be assessed.